

Update from NRS Reproductive Health and Childbirth Specialty Group September 2020



The common seal, *Phoca vitulina*, lives around the Scottish coast, comes ashore to breed in June & July and moults in September.

NHS RESEARCH SCOTLAND RESTARTING RESEARCH PATIENT SURVEY

This survey will capture confidence levels of patients returning to participate in NHS research, uncovering issues and concerns and considering how best to reassure and manage patient recruitment to clinical trials as important research restarts.

This will inform the work of the Restart Advisory Group and Restart Operations Group – convened by Chief Scientist Office to address restart issues and agree a common and consistent way forward.

This survey is an important part of restarting research. Please distribute widely.

To complete go to: <https://www.surveymonkey.co.uk/r/KZ2566Y>

COVID-19 URGENT PUBLIC HEALTH STUDIES. UPDATE

PAN-COVID. Pregnancy and Neonatal Outcomes in COVID-19. CPMS ID 45571.

PAN-C  **VID**

*The PAN-COVID study has now recruited **3430** women globally, from 173 hospital sites in 10 countries with ongoing new international inquiries (18th Sep 2020).*

Sites in Scotland include NHS Fife, Grampian, Greater Glasgow & Clyde, Highland, Lothian and Tayside.

The study team is very keen to work with all Health Boards in Scotland.

To register your interest: <https://pan-covid.org/>

The study welcomes and encourages retrospective data capture.

For queries please let us know or contact the PAN-COVID team: pan-covid@imperial.ac.uk.

NEW INTERNATIONAL STUDY LOOKING FOR SITES IN SCOTLAND

APOSTEL 8. Atosiban versus placebo in the treatment of late threatened preterm birth.

CPMS ID 35308; IRAS 230066. CI: Professor Jim Thornton, University of Nottingham. Funder: Netherlands Organisation for Health Research and Development.

A P O Threatened preterm birth complicates thousands of pregnancies annually. Tocolysis is
S T E historically a part of the treatment, but the effectiveness of the treatment has never been
L # 8 proven. The WHO has recently stated that the use of tocolytics should be re-evaluated.

The aim of this international multi-site study is to investigate if tocolysis with atosiban in late preterm birth (30-34 weeks) is effective compared with placebo in improving neonatal morbidity and mortality. [Summary](#)

NHS Lothian is on board!

Please let us know if you are interested and would like to receive more information and the protocol.

For further details please contact Nsama Mulongoti at Nsama.Mulongoti@nuh.nhs.uk and Apostel8@amc.nl.

Please send your Good News, queries, etc. to:
Abha (abha.maheshwari@abdn.ac.uk)
or Txaro (maria.amezaga@nhs.net)

STUDIES IN SET-UP OPEN TO NEW SITES

GBS3.

The clinical and cost-effectiveness of testing for Group B Streptococcus.

CPMS ID 42782; IRAS 263682.



Protocol and site selection questionnaire:
<https://nottingham.onlinesurveys.ac.uk/gbs3-site-selection-questionnaire>.

Please read the [HSIB report](#) (16th July 2020) which brings home the importance of the GBS3 trial. It examines severe brain injury, early neonatal death and intrapartum stillbirth associated with group B streptococcus infection.

The study team would like to hear from all centres in Scotland.

If you are encountering barriers to participation please contact Sarah Craig at GBS3@nottingham.ac.uk.

She will be happy to discuss any concerns.

The PARROT-2 Trial.

Placental growth factor Repeat sampling for Reduction of adverse perinatal Outcomes in women with suspected preeclampsia.
CPMS ID 43092; IRAS 265824.



*At present, the study team are only taking on new participating sites that are implementing **placental growth factor testing** as part of clinical care for pregnant women with suspected pre-eclampsia.*

Any interested sites in Scotland would have to implement this test. NHS Lothian is a site.

For further details please contact Alice Hurrell:
alice.hurrell@kcl.ac.uk.

FUNDING OPPORTUNITIES

[NRS Career Researcher Fellowships](#) are now open for applications. Deadline 11 November 2020.

The award is designed to provide funding for protected time, 2 sessions, to contribute to, conduct and lead Clinical Research. [Further details](#) and [Guidance 2020](#).

[Joint NES/CSO Postdoctoral Clinical Lectureships](#). Deadline 29 January 2021.

These positions are designed to provide opportunity for research time for medical doctors who have completed a research degree (PhD or MD) and are currently working towards the completion of speciality training. [More information and how to apply](#).



NEW NRS REPRODUCTIVE HEALTH AND CHILDBIRTH WEBPAGE UNDER DEVELOPMENT

We are working with NRS Communications to update our Specialty webpage in the NRS website, we will keep you updated on progress.